25 XP   0   0   10

Sutro Biopharma
Buy, Hold or Sell?

Let's analyse Sutro Biopharma together

PenkeI guess you are interested in Sutro Biopharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sutro Biopharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sutro Biopharma

I send you an email if I find something interesting about Sutro Biopharma.

Quick analysis of Sutro Biopharma (30 sec.)










What can you expect buying and holding a share of Sutro Biopharma? (30 sec.)

How much money do you get?

How much money do you get?
$0.01
When do you have the money?
1 year
How often do you get paid?
11.1%

What is your share worth?

Current worth
$1.84
Expected worth in 1 year
$-0.08
How sure are you?
29.6%

+ What do you gain per year?

Total Gains per Share
$-1.92
Return On Investment
-38.9%

For what price can you sell your share?

Current Price per Share
$4.93
Expected price per share
$2.89 - $5.93
How sure are you?
50%

1. Valuation of Sutro Biopharma (5 min.)




Live pricePrice per Share (EOD)

$4.93

Intrinsic Value Per Share

$-20.36 - $-23.93

Total Value Per Share

$-18.52 - $-22.09

2. Growth of Sutro Biopharma (5 min.)




Is Sutro Biopharma growing?

Current yearPrevious yearGrowGrow %
How rich?$112.3m$227.9m-$60.5m-36.2%

How much money is Sutro Biopharma making?

Current yearPrevious yearGrowGrow %
Making money-$43.7m-$30.2m-$13.4m-30.8%
Net Profit Margin-371.5%-296.0%--

How much money comes from the company's main activities?

3. Financial Health of Sutro Biopharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#364 / 1031

Most Revenue
#278 / 1031

Most Profit
#903 / 1031

Most Efficient
#724 / 1031

What can you expect buying and holding a share of Sutro Biopharma? (5 min.)

Welcome investor! Sutro Biopharma's management wants to use your money to grow the business. In return you get a share of Sutro Biopharma.

What can you expect buying and holding a share of Sutro Biopharma?

First you should know what it really means to hold a share of Sutro Biopharma. And how you can make/lose money.

Speculation

The Price per Share of Sutro Biopharma is $4.93. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sutro Biopharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sutro Biopharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.84. Based on the TTM, the Book Value Change Per Share is $-0.48 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sutro Biopharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.81-16.4%-0.71-14.3%-0.50-10.2%-0.37-7.5%-0.31-6.2%
Usd Book Value Change Per Share-0.70-14.1%-0.48-9.8%-0.22-4.5%0.214.2%0.071.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.70-14.1%-0.48-9.7%-0.22-4.5%0.214.2%0.071.4%
Usd Price Per Share3.47-5.21-8.47-10.83-8.57-
Price to Earnings Ratio-1.07--1.97--4.14--11.53--9.37-
Price-to-Total Gains Ratio-4.99--15.53--14.14-347.30-325.08-
Price to Book Ratio1.88-1.88-2.21-3.61-2.43-
Price-to-Total Gains Ratio-4.99--15.53--14.14-347.30-325.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.93
Number of shares202
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.480.21
Usd Total Gains Per Share-0.480.21
Gains per Quarter (202 shares)-96.8742.14
Gains per Year (202 shares)-387.48168.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12-389-3970168159
23-778-7841336328
35-1167-11711505497
46-1556-15581673666
58-1945-19452841835
69-2334-2332210091004
711-2723-2719211771173
812-3112-3106313461342
914-3501-3493315141511
1015-3890-3880316821680

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%3.024.00.011.1%3.024.00.011.1%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%6.013.01.030.0%8.016.03.029.6%8.016.03.029.6%
Dividend per Share2.00.02.050.0%3.00.09.025.0%3.00.017.015.0%3.00.024.011.1%3.00.024.011.1%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.013.01.030.0%8.016.03.029.6%8.016.03.029.6%

Fundamentals of Sutro Biopharma

About Sutro Biopharma

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-03-22 04:50:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sutro Biopharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sutro Biopharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sutro Biopharma to the Biotechnology industry mean.
  • A Net Profit Margin of -291.2% means that $-2.91 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sutro Biopharma:

  • The MRQ is -291.2%. The company is making a huge loss. -2
  • The TTM is -371.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-291.2%TTM-371.5%+80.3%
TTM-371.5%YOY-296.0%-75.5%
TTM-371.5%5Y-211.3%-160.2%
5Y-211.3%10Y-191.2%-20.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-291.2%-171.8%-119.4%
TTM-371.5%-205.8%-165.7%
YOY-296.0%-262.1%-33.9%
5Y-211.3%-455.6%+244.3%
10Y-191.2%-589.0%+397.8%
1.1.2. Return on Assets

Shows how efficient Sutro Biopharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sutro Biopharma to the Biotechnology industry mean.
  • -11.4% Return on Assets means that Sutro Biopharma generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sutro Biopharma:

  • The MRQ is -11.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.4%TTM-10.7%-0.7%
TTM-10.7%YOY-8.8%-1.9%
TTM-10.7%5Y-6.7%-4.0%
5Y-6.7%10Y-8.6%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.4%-12.5%+1.1%
TTM-10.7%-12.2%+1.5%
YOY-8.8%-11.2%+2.4%
5Y-6.7%-13.4%+6.7%
10Y-8.6%-14.7%+6.1%
1.1.3. Return on Equity

Shows how efficient Sutro Biopharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sutro Biopharma to the Biotechnology industry mean.
  • -43.9% Return on Equity means Sutro Biopharma generated $-0.44 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sutro Biopharma:

  • The MRQ is -43.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -28.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-43.9%TTM-28.2%-15.7%
TTM-28.2%YOY-13.3%-15.0%
TTM-28.2%5Y-12.5%-15.7%
5Y-12.5%10Y-9.2%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-43.9%-15.8%-28.1%
TTM-28.2%-15.7%-12.5%
YOY-13.3%-13.9%+0.6%
5Y-12.5%-18.3%+5.8%
10Y-9.2%-19.2%+10.0%

1.2. Operating Efficiency of Sutro Biopharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sutro Biopharma is operating .

  • Measures how much profit Sutro Biopharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sutro Biopharma to the Biotechnology industry mean.
  • An Operating Margin of -270.3% means the company generated $-2.70  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sutro Biopharma:

  • The MRQ is -270.3%. The company is operating very inefficient. -2
  • The TTM is -397.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-270.3%TTM-397.5%+127.2%
TTM-397.5%YOY-286.2%-111.3%
TTM-397.5%5Y-222.5%-175.0%
5Y-222.5%10Y-199.0%-23.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-270.3%-299.1%+28.8%
TTM-397.5%-210.1%-187.4%
YOY-286.2%-279.7%-6.5%
5Y-222.5%-459.9%+237.4%
10Y-199.0%-596.9%+397.9%
1.2.2. Operating Ratio

Measures how efficient Sutro Biopharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.70 means that the operating costs are $3.70 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sutro Biopharma:

  • The MRQ is 3.703. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.208. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.703TTM5.208-1.504
TTM5.208YOY3.885+1.323
TTM5.2085Y3.605+1.602
5Y3.60510Y3.780-0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7032.861+0.842
TTM5.2083.193+2.015
YOY3.8853.615+0.270
5Y3.6055.560-1.955
10Y3.7807.396-3.616

1.3. Liquidity of Sutro Biopharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sutro Biopharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.18 means the company has $5.18 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sutro Biopharma:

  • The MRQ is 5.180. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.724. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.180TTM4.724+0.456
TTM4.724YOY6.130-1.406
TTM4.7245Y6.519-1.795
5Y6.51910Y5.139+1.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1803.986+1.194
TTM4.7244.440+0.284
YOY6.1305.552+0.578
5Y6.5196.158+0.361
10Y5.1396.492-1.353
1.3.2. Quick Ratio

Measures if Sutro Biopharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sutro Biopharma to the Biotechnology industry mean.
  • A Quick Ratio of 8.76 means the company can pay off $8.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sutro Biopharma:

  • The MRQ is 8.764. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.249. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.764TTM7.249+1.515
TTM7.249YOY9.900-2.651
TTM7.2495Y10.526-3.277
5Y10.52610Y8.120+2.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.7643.638+5.126
TTM7.2494.168+3.081
YOY9.9005.515+4.385
5Y10.5266.012+4.514
10Y8.1206.209+1.911

1.4. Solvency of Sutro Biopharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sutro Biopharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sutro Biopharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Sutro Biopharma assets are financed with 74.0% credit (debt) and the remaining percentage (100% - 74.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sutro Biopharma:

  • The MRQ is 0.740. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.589. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.740TTM0.589+0.151
TTM0.589YOY0.355+0.234
TTM0.5895Y0.365+0.224
5Y0.36510Y0.751-0.386
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7400.335+0.405
TTM0.5890.330+0.259
YOY0.3550.267+0.088
5Y0.3650.367-0.002
10Y0.7510.378+0.373
1.4.2. Debt to Equity Ratio

Measures if Sutro Biopharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sutro Biopharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 284.3% means that company has $2.84 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sutro Biopharma:

  • The MRQ is 2.843. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.663. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.843TTM1.663+1.179
TTM1.663YOY0.580+1.084
TTM1.6635Y0.721+0.943
5Y0.72110Y0.902-0.181
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8430.376+2.467
TTM1.6630.398+1.265
YOY0.5800.334+0.246
5Y0.7210.429+0.292
10Y0.9020.476+0.426

2. Market Valuation of Sutro Biopharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sutro Biopharma generates.

  • Above 15 is considered overpriced but always compare Sutro Biopharma to the Biotechnology industry mean.
  • A PE ratio of -1.07 means the investor is paying $-1.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sutro Biopharma:

  • The EOD is -1.524. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.073. Based on the earnings, the company is expensive. -2
  • The TTM is -1.969. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.524MRQ-1.073-0.451
MRQ-1.073TTM-1.969+0.897
TTM-1.969YOY-4.136+2.166
TTM-1.9695Y-11.534+9.564
5Y-11.53410Y-9.371-2.163
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.524-2.643+1.119
MRQ-1.073-2.418+1.345
TTM-1.969-2.742+0.773
YOY-4.136-4.123-0.013
5Y-11.534-6.257-5.277
10Y-9.371-6.478-2.893
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sutro Biopharma:

  • The EOD is -2.221. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.563. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.345. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.221MRQ-1.563-0.658
MRQ-1.563TTM-2.345+0.782
TTM-2.345YOY-6.562+4.216
TTM-2.3455Y-9.929+7.583
5Y-9.92910Y-7.175-2.753
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.221-3.244+1.023
MRQ-1.563-2.939+1.376
TTM-2.345-3.478+1.133
YOY-6.562-5.592-0.970
5Y-9.929-8.473-1.456
10Y-7.175-8.881+1.706
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sutro Biopharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.88 means the investor is paying $1.88 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sutro Biopharma:

  • The EOD is 2.675. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.883. Based on the equity, the company is underpriced. +1
  • The TTM is 1.876. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.675MRQ1.883+0.792
MRQ1.883TTM1.876+0.007
TTM1.876YOY2.214-0.338
TTM1.8765Y3.607-1.731
5Y3.60710Y2.432+1.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6752.124+0.551
MRQ1.8832.041-0.158
TTM1.8762.118-0.242
YOY2.2142.915-0.701
5Y3.6073.682-0.075
10Y2.4324.114-1.682
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sutro Biopharma.

3.1. Institutions holding Sutro Biopharma

Institutions are holding 97.573% of the shares of Sutro Biopharma.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc9.55470.00065823922-162678-2.7174
2023-12-31Suvretta Capital Management, LLC9.47971.12075778188-105505-1.7932
2023-12-31Adage Capital Partners Gp LLC7.32990.03974467796136266443.8843
2023-09-30Bvf Inc5.49260.3133334794600
2023-12-31Rubric Capital Management LP5.48750.2977334481000
2023-12-31Vanguard Group Inc4.74130.00032890000212380.7403
2023-12-31Franklin Resources Inc4.53240.00552762636-71725-2.5306
2023-09-30Holocene Advisors, LP3.49920.0324213287300
2023-12-31Goldman Sachs Group Inc3.480.00082121164102977394.3542
2023-12-31Kynam Capital Management, LP3.2840.9514200172744905228.9212
2023-12-31Baillie Gifford & Co Limited.3.06280.00641866850-804-0.043
2023-12-31Samsara BioCapital, LLC2.7491.1183167557900
2023-12-31Millennium Management LLC2.51980.0029153586929661823.9353
2023-12-31Geode Capital Management, LLC2.06590.00061259237620855.1861
2023-12-31Parkman Healthcare Partners LLC1.97270.72661202431202631.7141
2023-12-31State Street Corporation1.90550.00021161465556805.0353
2023-12-31Dimensional Fund Advisors, Inc.1.87150.00141140760109370.968
2023-12-31Eversept Partners, LLC1.73320.3982105646128682337.2673
2023-12-31Acadian Asset Management LLC1.51430.015492302914916219.2749
2023-12-31Candriam Luxembourg S.C.A.1.47360.0266898234-640000-41.6062
Total 77.74965.05947390977+2763583+5.8%

3.2. Funds holding Sutro Biopharma

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.98520.0006181959600
2024-02-29iShares Russell 2000 ETF2.44010.01171487344-243-0.0163
2024-01-31Baillie Gifford Global Discovery A Acc1.76350.59611074929135421.2759
2023-12-31Franklin US Small Cap Growth Equity1.58060.1491963449-5000-0.5163
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.3040.003879485800
2023-12-31Edinburgh Worldwide Ord1.23160.3205750723-4-0.0005
2023-12-31Fidelity Small Cap Index0.99340.0102605479114641.9299
2024-02-01iShares Russell 2000 Value ETF0.92260.02095623287120.1268
2023-12-31Candriam Global Equities Oncology0.90290.1272550369-555000-50.2095
2024-02-29Belfius Equities Cure C Cap0.90290.143155036900
2023-10-31Goldman Sachs Small Cp Val Insghts Instl0.74530.150845426600
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.59950.004336541100
2024-01-31BlackRock Advantage Small Cap Core Instl0.5880.043535842500
2024-01-31Candriam Eqs L Biotech C USD Cap0.57060.091934781200
2024-01-31Fidelity Extended Market Index0.49070.003629912400
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.37570.011922897700
2024-02-29Vanguard Russell 2000 ETF0.35760.0112217999170888.5053
2023-12-31Fisher US Small Cap Opportunities0.32240.648619651700
2023-08-10AMOne Fisher US Micro Equity Fund0.32240.58331965171965170
2023-10-31Goldman Sachs Small Cap Eq Insghts Instl0.28440.149317334900
Total 19.68343.081611997841-320924-2.7%

3.3. Insider Transactions

Insiders are holding 1.179% of the shares of Sutro Biopharma.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-29Nicki VasquezSELL121855
2023-08-28Brunilda ShtyllaSELL154284.71
2023-08-25Brunilda ShtyllaSELL116134.59

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sutro Biopharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.695-0.481-31%-0.221-68%0.208-434%0.068-1118%
Book Value Per Share--1.8432.746-33%3.739-51%3.228-43%2.183-16%
Current Ratio--5.1804.724+10%6.130-16%6.519-21%5.139+1%
Debt To Asset Ratio--0.7400.589+26%0.355+109%0.365+103%0.751-1%
Debt To Equity Ratio--2.8431.663+71%0.580+390%0.721+294%0.902+215%
Dividend Per Share---0.002-100%0.000-100%0.000-100%0.000-100%
Eps---0.809-0.707-13%-0.503-38%-0.371-54%-0.308-62%
Free Cash Flow Per Share---0.555-0.639+15%-0.005-99%-0.301-46%-0.237-57%
Free Cash Flow To Equity Per Share---0.649-0.012-98%0.145-547%0.219-396%0.207-414%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---23.931--------
Intrinsic Value_10Y_min---20.361--------
Intrinsic Value_1Y_max---1.520--------
Intrinsic Value_1Y_min---1.493--------
Intrinsic Value_3Y_max---5.237--------
Intrinsic Value_3Y_min---4.986--------
Intrinsic Value_5Y_max---9.760--------
Intrinsic Value_5Y_min---9.001--------
Market Cap300499276.000+30%211507604.000317261406.000-33%515968838.000-59%659879343.200-68%522662402.370-60%
Net Profit Margin---2.912-3.715+28%-2.960+2%-2.113-27%-1.912-34%
Operating Margin---2.703-3.975+47%-2.862+6%-2.225-18%-1.990-26%
Operating Ratio--3.7035.208-29%3.885-5%3.605+3%3.780-2%
Pb Ratio2.675+30%1.8831.876+0%2.214-15%3.607-48%2.432-23%
Pe Ratio-1.524-42%-1.073-1.969+84%-4.136+285%-11.534+975%-9.371+773%
Price Per Share4.930+30%3.4705.205-33%8.465-59%10.826-68%8.575-60%
Price To Free Cash Flow Ratio-2.221-42%-1.563-2.345+50%-6.562+320%-9.929+535%-7.175+359%
Price To Total Gains Ratio-7.093-42%-4.992-15.526+211%-14.137+183%347.298-101%325.078-102%
Quick Ratio--8.7647.249+21%9.900-11%10.526-17%8.120+8%
Return On Assets---0.114-0.107-6%-0.088-23%-0.067-41%-0.086-25%
Return On Equity---0.439-0.282-36%-0.133-70%-0.125-72%-0.092-79%
Total Gains Per Share---0.695-0.480-31%-0.221-68%0.209-433%0.069-1114%
Usd Book Value--112347000.000167380750.000-33%227930000.000-51%196749900.000-43%133031777.778-16%
Usd Book Value Change Per Share---0.695-0.481-31%-0.221-68%0.208-434%0.068-1118%
Usd Book Value Per Share--1.8432.746-33%3.739-51%3.228-43%2.183-16%
Usd Dividend Per Share---0.002-100%0.000-100%0.000-100%0.000-100%
Usd Eps---0.809-0.707-13%-0.503-38%-0.371-54%-0.308-62%
Usd Free Cash Flow---33830000.000-38948250.000+15%-298750.000-99%-18317650.000-46%-14460518.519-57%
Usd Free Cash Flow Per Share---0.555-0.639+15%-0.005-99%-0.301-46%-0.237-57%
Usd Free Cash Flow To Equity Per Share---0.649-0.012-98%0.145-547%0.219-396%0.207-414%
Usd Market Cap300499276.000+30%211507604.000317261406.000-33%515968838.000-59%659879343.200-68%522662402.370-60%
Usd Price Per Share4.930+30%3.4705.205-33%8.465-59%10.826-68%8.575-60%
Usd Profit---49284000.000-43738000.000-11%-30247750.000-39%-21998200.000-55%-18159666.667-63%
Usd Revenue--16924000.00012160500.000+39%17448500.000-3%14233150.000+19%14828407.407+14%
Usd Total Gains Per Share---0.695-0.480-31%-0.221-68%0.209-433%0.069-1114%
 EOD+5 -3MRQTTM+11 -24YOY+6 -295Y+3 -3210Y+7 -28

4.2. Fundamental Score

Let's check the fundamental score of Sutro Biopharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.524
Price to Book Ratio (EOD)Between0-12.675
Net Profit Margin (MRQ)Greater than0-2.912
Operating Margin (MRQ)Greater than0-2.703
Quick Ratio (MRQ)Greater than18.764
Current Ratio (MRQ)Greater than15.180
Debt to Asset Ratio (MRQ)Less than10.740
Debt to Equity Ratio (MRQ)Less than12.843
Return on Equity (MRQ)Greater than0.15-0.439
Return on Assets (MRQ)Greater than0.05-0.114
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Sutro Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.245
Ma 20Greater thanMa 504.254
Ma 50Greater thanMa 1004.461
Ma 100Greater thanMa 2003.882
OpenGreater thanClose4.260
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets431,734
Total Liabilities319,387
Total Stockholder Equity112,347
 As reported
Total Liabilities 319,387
Total Stockholder Equity+ 112,347
Total Assets = 431,734

Assets

Total Assets431,734
Total Current Assets381,254
Long-term Assets50,480
Total Current Assets
Cash And Cash Equivalents 81,834
Short-term Investments 273,317
Net Receivables 16,627
Other Current Assets 9,476
Total Current Assets  (as reported)381,254
Total Current Assets  (calculated)381,254
+/-0
Long-term Assets
Property Plant Equipment 46,340
Long-term Assets  (as reported)50,480
Long-term Assets  (calculated)46,340
+/- 4,140

Liabilities & Shareholders' Equity

Total Current Liabilities73,606
Long-term Liabilities245,781
Total Stockholder Equity112,347
Total Current Liabilities
Short-term Debt 13,311
Short Long Term Debt 7,137
Accounts payable 5,525
Other Current Liabilities 30,787
Total Current Liabilities  (as reported)73,606
Total Current Liabilities  (calculated)56,760
+/- 16,846
Long-term Liabilities
Capital Lease Obligations 31,038
Long-term Liabilities  (as reported)245,781
Long-term Liabilities  (calculated)31,038
+/- 214,743
Total Stockholder Equity
Common Stock61
Retained Earnings -590,473
Accumulated Other Comprehensive Income 7
Other Stockholders Equity 702,752
Total Stockholder Equity (as reported)112,347
Total Stockholder Equity (calculated)112,347
+/-0
Other
Capital Stock61
Cash and Short Term Investments 355,151
Common Stock Shares Outstanding 60,599
Current Deferred Revenue23,983
Liabilities and Stockholders Equity 431,734
Net Debt -43,659
Net Invested Capital 119,484
Net Working Capital 307,648
Property Plant and Equipment Gross 46,340
Short Long Term Debt Total 38,175



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-03-312016-12-31
> Total Assets 
69,277
0
0
40,769
45,181
45,181
145,026
223,139
223,139
188,812
171,678
156,370
153,875
277,538
307,237
394,111
358,528
359,788
371,472
341,408
303,675
385,620
400,700
406,944
358,016
464,899
431,734
431,734464,899358,016406,944400,700385,620303,675341,408371,472359,788358,528394,111307,237277,538153,875156,370171,678188,812223,139223,139145,02645,18145,18140,7690069,277
   > Total Current Assets 
49,688
0
0
25,629
30,223
30,223
127,372
209,946
209,946
162,223
135,567
128,568
127,459
258,490
292,298
378,182
266,001
277,615
250,729
218,515
228,742
331,511
346,553
353,153
286,367
411,985
381,254
381,254411,985286,367353,153346,553331,511228,742218,515250,729277,615266,001378,182292,298258,490127,459128,568135,567162,223209,946209,946127,37230,22330,22325,6290049,688
       Cash And Cash Equivalents 
11,593
0
0
22,020
25,420
25,420
41,353
125,298
125,298
19,390
11,954
4,960
43,565
65,348
64,370
206,152
55,818
56,392
30,707
30,414
28,901
79,115
96,779
47,254
251,466
235,095
81,834
81,834235,095251,46647,25496,77979,11528,90130,41430,70756,39255,818206,15264,37065,34843,5654,96011,95419,390125,298125,29841,35325,42025,42022,0200011,593
       Short-term Investments 
35,928
0
0
0
0
0
81,597
79,194
79,194
133,774
113,209
112,904
71,826
185,109
216,862
161,985
195,410
202,312
198,994
167,524
180,244
146,521
227,469
287,110
25,028
156,547
273,317
273,317156,54725,028287,110227,469146,521180,244167,524198,994202,312195,410161,985216,862185,10971,826112,904113,209133,77479,19479,19481,5970000035,928
       Net Receivables 
577
0
0
1,624
3,184
3,184
2,443
2,489
2,489
6,500
7,531
6,298
9,079
5,102
7,483
5,559
7,227
9,160
12,330
12,454
11,686
97,671
11,241
7,122
9,873
9,999
16,627
16,6279,9999,8737,12211,24197,67111,68612,45412,3309,1607,2275,5597,4835,1029,0796,2987,5316,5002,4892,4892,4433,1843,1841,62400577
       Other Current Assets 
1,590
0
0
1,985
0
1,619
1,979
2,965
2,965
2,559
2,873
4,406
2,989
2,931
3,583
4,486
7,546
9,751
8,698
8,123
7,911
8,204
11,064
11,667
17,696
10,344
9,476
9,47610,34417,69611,66711,0648,2047,9118,1238,6989,7517,5464,4863,5832,9312,9894,4062,8732,5592,9652,9651,9791,61901,985001,590
   > Long-term Assets 
0
0
0
15,140
0
14,958
17,654
13,193
13,193
26,589
36,111
27,802
26,416
19,048
14,939
15,929
92,527
82,173
120,743
122,893
74,933
54,109
54,147
53,791
71,649
52,914
50,480
50,48052,91471,64953,79154,14754,10974,933122,893120,74382,17392,52715,92914,93919,04826,41627,80236,11126,58913,19313,19317,65414,958015,140000
       Property Plant Equipment 
18,690
0
0
13,997
11,860
11,860
11,673
10,934
10,934
9,273
8,522
9,633
9,527
11,265
11,945
12,935
14,829
18,669
53,448
51,591
51,657
51,316
51,354
51,064
49,831
48,774
46,340
46,34048,77449,83151,06451,35451,31651,65751,59153,44818,66914,82912,93511,94511,2659,5279,6338,5229,27310,93410,93411,67311,86011,86013,9970018,690
       Long Term Investments 
0
0
0
0
0
0
0
0
13,747
15,062
25,223
15,609
14,191
5,647
0
0
74,615
60,006
64,279
68,775
20,699
0
0
0
0
0
0
00000020,69968,77564,27960,00674,615005,64714,19115,60925,22315,06213,74700000000
       Long-term Assets Other 
0
0
0
1,143
0
3,098
5,981
2,259
2,259
2,254
2,366
2,560
2,698
2,136
2,994
2,994
3,083
3,498
3,016
2,527
2,577
2,793
2,793
34,747
-142,148
37,489
38,183
38,18337,489-142,14834,7472,7932,7932,5772,5273,0163,4983,0832,9942,9942,1362,6982,5602,3662,2542,2592,2595,9813,09801,143000
> Total Liabilities 
57,673
0
0
149,770
40,679
177,200
286,460
91,600
91,600
69,257
61,772
58,581
71,790
70,781
63,118
62,063
51,190
52,288
87,892
88,844
83,303
176,562
170,974
189,896
172,603
310,184
319,387
319,387310,184172,603189,896170,974176,56283,30388,84487,89252,28851,19062,06363,11870,78171,79058,58161,77269,25791,60091,600286,460177,20040,679149,7700057,673
   > Total Current Liabilities 
50,181
0
0
31,956
19,226
19,226
36,905
36,423
36,423
36,099
35,859
32,967
32,008
35,460
29,910
29,597
22,660
26,125
35,455
41,736
38,760
44,572
58,288
66,547
126,039
67,125
73,606
73,60667,125126,03966,54758,28844,57238,76041,73635,45526,12522,66029,59729,91035,46032,00832,96735,85936,09936,42336,42336,90519,22619,22631,9560050,181
       Short-term Debt 
0
0
0
14,634
2,000
2,000
3,182
4,724
4,724
5,806
5,843
1,000
2,944
4,520
5,890
8,823
4,496
3,125
7,695
10,412
13,578
13,620
15,131
17,085
18,493
16,131
13,311
13,31116,13118,49317,08515,13113,62013,57810,4127,6953,1254,4968,8235,8904,5202,9441,0005,8435,8064,7244,7243,1822,0002,00014,634000
       Short Long Term Debt 
0
0
0
14,634
2,000
2,000
3,182
4,724
5,766
5,806
5,843
1,000
0
0
0
0
0
3,125
6,250
9,375
12,500
12,500
12,500
12,500
13,242
10,197
7,137
7,13710,19713,24212,50012,50012,50012,5009,3756,2503,125000001,0005,8435,8065,7664,7243,1822,0002,00014,634000
       Accounts payable 
3,394
0
0
2,902
2,688
2,688
4,594
9,278
3,061
4,516
4,549
5,584
5,839
4,901
4,879
5,544
5,891
7,642
11,173
11,327
10,705
12,567
12,443
4,797
23,807
3,856
5,525
5,5253,85623,8074,79712,44312,56710,70511,32711,1737,6425,8915,5444,8794,9015,8395,5844,5494,5163,0619,2784,5942,6882,6882,902003,394
       Other Current Liabilities 
46,787
0
0
3,711
10,458
4,178
4,900
22,421
7,064
4,397
5,217
6,918
352
2,536
3,438
627
185
7,230
8,783
14,501
8,198
11,895
14,794
27,906
-18,493
29,102
30,787
30,78729,102-18,49327,90614,79411,8958,19814,5018,7837,2301856273,4382,5363526,9185,2174,3977,06422,4214,9004,17810,4583,7110046,787
   > Long-term Liabilities 
0
0
0
117,814
0
157,974
249,555
55,177
55,177
33,158
25,913
25,614
39,782
35,321
33,208
32,466
28,530
26,163
52,437
47,108
44,543
131,990
112,686
123,349
46,564
243,059
245,781
245,781243,05946,564123,349112,686131,99044,54347,10852,43726,16328,53032,46633,20835,32139,78225,61425,91333,15855,17755,177249,555157,9740117,814000
       Long term Debt Total 
0
0
0
0
0
0
11,500
10,000
8,500
7,000
5,500
8,876
24,155
24,281
24,411
24,545
24,680
21,694
18,714
15,738
12,762
9,779
6,783
0
0
0
0
00006,7839,77912,76215,73818,71421,69424,68024,54524,41124,28124,1558,8765,5007,0008,50010,00011,500000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-14,634
-2,000
-2,000
-3,182
-4,724
-4,724
-5,806
-5,843
-1,000
-2,944
-4,520
-5,890
-8,823
-4,496
-3,125
25,823
21,849
19,134
19,569
18,538
17,074
14,829
16,329
17,727
17,72716,32914,82917,07418,53819,56919,13421,84925,823-3,125-4,496-8,823-5,890-4,520-2,944-1,000-5,843-5,806-4,724-4,724-3,182-2,000-2,000-14,634000
       Warrants
0
0
0
0
0
0
374,491
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000374,491000000
       Long-term Liabilities Other 
0
0
0
0
0
0
1,531
44,701
121
125
129
134
141
148
8,517
481
1,460
844
33,723
146
31,781
142
105,903
119
113,117
0
0
00113,117119105,90314231,78114633,7238441,4604818,51714814113412912512144,7011,531000000
       Deferred Long Term Liability 
0
0
0
500
1,200
1,200
49,278
476
0
456
435
409
373
330
280
1,340
2,390
3,432
0
0
0
0
0
0
0
0
0
0000000003,4322,3901,340280330373409435456047649,2781,2001,200500000
> Total Stockholder Equity
11,604
-90,901
0
-109,001
-109,001
-132,019
-141,434
131,539
131,539
119,555
109,906
97,789
82,085
206,757
244,119
332,048
307,338
307,500
283,580
252,564
220,372
209,058
229,726
217,048
185,413
154,715
112,347
112,347154,715185,413217,048229,726209,058220,372252,564283,580307,500307,338332,048244,119206,75782,08597,789109,906119,555131,539131,539-141,434-132,019-109,001-109,0010-90,90111,604
   Common Stock
16
0
0
17
17
17
-867
23
23
23
23
23
23
36
38
46
46
46
46
46
47
49
55
58
60
60
61
6160605855494746464646463836232323232323-8671717170016
   Retained Earnings Total Equity00-502,6650-418,021-398,533-372,521-333,411-295,286-264,384-258,232-227,873-168,329-185,468-215,340-195,745-180,956-168,0440-150,328-148,835000000
   Accumulated Other Comprehensive Income 
0
0
0
-25,014
0
0
-27
-29,296
-47
213
223
165
28
398
237
129
129
-45
-30
-314
-1,152
-1,356
-1,336
-618
-107
16
7
716-107-618-1,336-1,356-1,152-314-30-4512912923739828165223213-47-29,296-2700-25,014000
   Capital Surplus 
0
0
0
0
0
0
7,428
281,891
284,890
287,363
290,616
293,346
297,374
391,791
412,173
559,746
565,524
571,883
578,850
586,243
593,998
608,898
649,028
0
688,125
0
0
00688,1250649,028608,898593,998586,243578,850571,883565,524559,746412,173391,791297,374293,346290,616287,363284,890281,8917,428000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
-224
0
0
-96,495
-208
-129,141
7,428
-47
281,891
287,363
290,616
293,346
297,374
391,791
412,173
559,746
565,524
571,883
578,850
586,243
593,998
608,898
649,028
670,223
688,125
695,828
702,752
702,752695,828688,125670,223649,028608,898593,998586,243578,850571,883565,524559,746412,173391,791297,374293,346290,616287,363281,891-477,428-129,141-208-96,49500-224



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue48,642
Cost of Revenue--
Gross Profit-48,642
 
Operating Income (+$)
Gross Profit-
Operating Expense-230,294
Operating Income-181,652-230,294
 
Operating Expense (+$)
Research Development169,795
Selling General Administrative60,499
Selling And Marketing Expenses-
Operating Expense230,294230,294
 
Net Interest Income (+$)
Interest Income12,080
Interest Expense-14,325
Other Finance Cost-0
Net Interest Income-2,245
 
Pretax Income (+$)
Operating Income-181,652
Net Interest Income-2,245
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-170,067-195,482
EBIT - interestExpense = -14,325
-172,452
-158,127
Interest Expense14,325
Earnings Before Interest and Taxes (EBIT)--155,742
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-170,067
Tax Provision-2,385
Net Income From Continuing Ops-172,452-172,452
Net Income-172,452
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net13,8302,245
 

Technical Analysis of Sutro Biopharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sutro Biopharma. The general trend of Sutro Biopharma is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sutro Biopharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sutro Biopharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.4832 < 5.63 < 5.93.

The bearish price targets are: 3.2 > 2.935 > 2.89.

Tweet this
Sutro Biopharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sutro Biopharma. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sutro Biopharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sutro Biopharma. The current macd is -0.16513056.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sutro Biopharma price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sutro Biopharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sutro Biopharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Sutro Biopharma Daily Moving Average Convergence/Divergence (MACD) ChartSutro Biopharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sutro Biopharma. The current adx is 20.71.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sutro Biopharma shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Sutro Biopharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sutro Biopharma. The current sar is 3.21.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sutro Biopharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sutro Biopharma. The current rsi is 60.25. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Sutro Biopharma Daily Relative Strength Index (RSI) ChartSutro Biopharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sutro Biopharma. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sutro Biopharma price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sutro Biopharma Daily Stochastic Oscillator ChartSutro Biopharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sutro Biopharma. The current cci is 57.65.

Sutro Biopharma Daily Commodity Channel Index (CCI) ChartSutro Biopharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sutro Biopharma. The current cmo is 32.79.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sutro Biopharma Daily Chande Momentum Oscillator (CMO) ChartSutro Biopharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sutro Biopharma. The current willr is -5.97826087.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Sutro Biopharma Daily Williams %R ChartSutro Biopharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sutro Biopharma.

Sutro Biopharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sutro Biopharma. The current atr is 0.39250901.

Sutro Biopharma Daily Average True Range (ATR) ChartSutro Biopharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sutro Biopharma. The current obv is 35,421,764.

Sutro Biopharma Daily On-Balance Volume (OBV) ChartSutro Biopharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sutro Biopharma. The current mfi is 42.29.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Sutro Biopharma Daily Money Flow Index (MFI) ChartSutro Biopharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sutro Biopharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Sutro Biopharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sutro Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.245
Ma 20Greater thanMa 504.254
Ma 50Greater thanMa 1004.461
Ma 100Greater thanMa 2003.882
OpenGreater thanClose4.260
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sutro Biopharma with someone you think should read this too:
  • Are you bullish or bearish on Sutro Biopharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sutro Biopharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sutro Biopharma

I send you an email if I find something interesting about Sutro Biopharma.


Comments

How you think about this?

Leave a comment

Stay informed about Sutro Biopharma.

Receive notifications about Sutro Biopharma in your mailbox!